ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

A novel eye drop formulation shows antioxidant effects and may protect corneal epithelial cells, according to research presented at AOA 2025.

Top Cleveland Clinic and University of Iowa eye doctors explain it's not just blurry vision or irritation—and not just any eye drop will help.

Patients, especially contact lens wearers, may develop microplastic toxicity and exhibit symptoms such as dry eye, a study ...

Itchy eyes can be uncomfortable, even crazy-making, and many of us experience them at one time or another. If you’re ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.

Alcon produces contact lenses, dry eye drops, gels and other related products. Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to ...

Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease By Kevin Dunleavy May 29, 2025 10:20am Alcon Novartis FDA approval dry eye disease ...

GENEVA - Alcon (SIX/NYSE: ALC), a prominent player in the Healthcare Equipment & Supplies sector with a market capitalization of $42.25 billion, announced the FDA approval of TRYPTYR (acoltremon ...

Stifel’s optimism is tied to the upcoming PDUFA date for Alcon’s AR-15512 eyedrop treatment for dry eye disease, despite some concerns about the competitive landscape and product launch ...

Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the ...

Swiss eye care firm Alcon drops after earnings miss, flags tariff impact. May 14, 2025 7:03 AM ET Alcon Inc. ... Alcon's shares were on track for their worst day since March 2020.